| WASHINGTON, D.C. – The Foundation for Drug Policy Solutions (FDPS) today urged Congress to put veteran safety ahead of speed following Wednesday’s House Veterans’ Affairs Subcommittee on Health hearing on psychedelic-assisted therapy. VA has identified 10 facilities to serve as early sites so it can be “the first healthcare system in the nation to deliver these treatments to veterans” once regulators sign off. Andrew Gradison, a senior adviser to the Veterans Health Administration, told the subcommittee that “our demand for these treatments will exceed our ability to supply them” and that private providers “may not be able to create the infrastructure to meet the standards that the FDA sets.” Ranking Member Julia Brownley (D-CA), who welcomed the prospect of approval, warned it will likely fuel growth in “wellness centers marketing themselves to veterans,” as off-label ketamine did. Dr. Leith States, former Acting Assistant Secretary for Health at HHS, warned that “a referral cannot become a transfer of accountability,” and the American Psychological Association called for explicit policies on physical contact, chaperones, and independent review of misconduct complaints. “Every veteran deserves treatments proven safe and effective, not treatments rushed out on hype,” said Dr. Kevin A. Sabet, President and CEO of FDPS and SAM and a three-time White House drug policy adviser. “VA’s own witness just admitted that demand will outstrip VA’s capacity and that private clinics may not meet FDA’s safety standards. That is a recipe for veterans being funneled into cash-only wellness centers. We saw it with ketamine clinics, and we saw it with an MDMA application the FDA rejected over serious questions about its data. Veterans should never be the test market for an industry looking for its next customer.” FDPS and SAM are calling on the committee to require full FDA approval before any VA delivery or community care referrals, to bar referrals to wellness centers that cannot meet clinical standards, and to require public reporting of adverse events from the VA’s ongoing psychedelic studies. |

